Tag: KDC-MN-037

  • Imuracetam

    Imidazole-fused pyrrolidinone racetam

    An obscure imidazole-substituted racetam from early Soviet pharmacology with sparse published literature.

    Abstract

    Imuracetam is an imidazole-substituted piracetam analog reported in early Soviet nootropic pharmacology literature. Published data are extremely sparse; the compound never advanced to clinical trials in any jurisdiction and is not approved as a medicine in any market. The structural innovation is fusion of an imidazole ring to the pyrrolidinone scaffold, intended to enhance lipophilicity and modulate the cholinergic profile. Mechanism is incompletely characterized but is thought to overlap with piracetam pharmacology (membrane fluidity, indirect cholinergic, weak AMPA modulation). The compound is occasionally available from research chemical vendors but the chain of custody and analytical characterization on commercial samples is generally unverifiable. Investigators using imuracetam should obtain analytical confirmation of identity and purity before use. There is no human pharmacokinetic data, no formal safety profile, and no dose-finding data in any species. This monograph is provided for completeness of the racetam class survey and as a cautionary entry: not every compound with a “racetam” suffix has substantive published support, and obscurity is itself a research consideration.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.